Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Alliant Energy Corporation — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Alliant Energy Corporation trades at $67.51 (market cap $17.36B). The key difference: Alliant Energy Corporation is far larger — about 6.1× Dyne Therapeutics Inc. Common Stock's market cap, and Alliant Energy Corporation pays a 3.2% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Alliant Energy Corporation for 65 Days on average.
| DYN | LNT | |
|---|---|---|
Market Cap | $2.86B | $17.36B |
Volume | 3,341,579 | 1,948,386 |
Sector | Health | Utilities |
52-Week High | $26.78 | $78.03 |
52-Week Low | $14.60 | $63.21 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $2.18B | $29.46B |
Dividend Yield | — | 3.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
LNT trades at $67.51, up 1.58% with a bullish technical signal despite mixed momentum indicators. The company shows solid fundamentals with Q2 2026 earnings beating expectations at $0.65 per share and maintaining 18.45% net margins. Recent news highlights institutional accumulation and a $13.4 billion capital investment plan through 2029 supporting long-term growth. Analyst consensus remains positive with a $75.17 price target and no sell ratings.
LNT presents a favorable risk-reward profile with strong utility operations, consistent dividend growth, and data center demand driving revenue. Key risks include rising debt levels (48.48% debt-to-asset ratio) and interest rate sensitivity. The stock offers defensive value with upside potential to analyst targets, though investors should monitor execution of the large capex plan and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
